.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
QuintilesIMS
Covington
McKesson
Novartis
Express Scripts
Federal Trade Commission
Baxter
Fish and Richardson
Merck

Generated: July 25, 2017

DrugPatentWatch Database Preview

Medicis Company Profile

« Back to Dashboard

What is the competitive landscape for MEDICIS, and when can generic versions of MEDICIS drugs launch?

MEDICIS has twenty approved drugs.

There are twenty-six US patents protecting MEDICIS drugs.

There are one hundred and seventy-five patent family members on MEDICIS drugs in forty-nine countries.

Summary for Applicant: Medicis

Patents:26
Tradenames:19
Ingredients:17
NDAs:20
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medicis
LOPROX
ciclopirox
SHAMPOO;TOPICAL021159-001Feb 28, 2003ATRXYesYes► Subscribe► Subscribe ► Subscribe
Medicis
LUZU
luliconazole
CREAM;TOPICAL204153-001Nov 14, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-004Jul 23, 2009RXYesNo► Subscribe► Subscribe ► Subscribe
Medicis
METROGEL-VAGINAL
metronidazole
GEL;VAGINAL020208-001Aug 17, 1992ABRXYesYes► Subscribe► Subscribe► Subscribe
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-006Aug 27, 2010ABRXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Medicis

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medicis
MAXAIR
pirbuterol acetate
AEROSOL, METERED;INHALATION020014-001Nov 30, 1992► Subscribe► Subscribe
Medicis
ZIANA
clindamycin phosphate; tretinoin
GEL;TOPICAL050802-001Nov 7, 2006► Subscribe► Subscribe
Medicis
METROGEL-VAGINAL
metronidazole
GEL;VAGINAL020208-001Aug 17, 1992► Subscribe► Subscribe
Medicis
METROGEL-VAGINAL
metronidazole
GEL;VAGINAL020208-001Aug 17, 1992► Subscribe► Subscribe
Medicis
METROGEL-VAGINAL
metronidazole
GEL;VAGINAL020208-001Aug 17, 1992► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for MEDICIS drugs

Drugname Dosage Strength Tradename Submissiondate
imiquimod
Cream2.5%
ZYCLARA
6/17/2014
imiquimod
Cream3.75%
ZYCLARA
8/8/2012
minocycline hydrochloride
Extended-release Tablet105 rng
SOLODYN
12/28/2010
clindamycin phosphate and tretinoin
Gel1.2%/0.025%
ZIANA
12/17/2010
minocycline hydrochloride
Extended-release Tablet55 mg and 80 mg
SOLODYN
12/2/2010
minocycline hydrochloride
Extended-release Tablets65 mg and 115 mg
SOLODYN
11/19/2009
fluocinonide
Cream0.10%
VANOS
1/31/2008
imiquimod
Cream5%
ALDARA
10/17/2006
ciclopirox
Gel0.77%
LOPROX
5/10/2006
metronidazole
Vaginal Gel0.75%
METROGEL-VAGINAL
9/2/2004

Non-Orange Book Patents for Medicis

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,271,973Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy► Subscribe
6,517,847 Topical gel delivery system► Subscribe
9,085,554Method of evaluating pharmaceutical preparation containing luliconazole and index substance► Subscribe
7,771,733Compositions and methods for enhancing corticosteroid delivery► Subscribe
9,370,5092.times.2.times.2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Medicis Drugs

Country Document Number Estimated Expiration
South Korea20080036246► Subscribe
Denmark1304992► Subscribe
European Patent Office2895165► Subscribe
China1617730► Subscribe
Finland119357► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Medicis Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/042United Kingdom► SubscribePRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020418
C/GB08/036United Kingdom► SubscribePRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
C0041France► SubscribePRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
C0052France► SubscribePRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Julphar
US Department of Justice
Cantor Fitzgerald
Dow
Johnson and Johnson
Daiichi Sankyo
Covington
Cerilliant
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot